Cargando…

Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis

Liver-related diseases are the third-leading causes (9.3%) of mortality in type 2 diabetes (T2D) in Japan. T2D is closely associated with nonalcoholic fatty liver disease (NAFLD), which is the most prevalent chronic liver disease worldwide. Nonalcoholic steatohepatitis (NASH), a severe form of NAFLD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sumida, Yoshio, Yoneda, Masashi, Tokushige, Katsutoshi, Kawanaka, Miwa, Fujii, Hideki, Yoneda, Masato, Imajo, Kento, Takahashi, Hirokazu, Eguchi, Yuichiro, Ono, Masafumi, Nozaki, Yuichi, Hyogo, Hideyuki, Koseki, Masahiro, Yoshida, Yuichi, Kawaguchi, Takumi, Kamada, Yoshihiro, Okanoue, Takeshi, Nakajima, Atsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139365/ https://www.ncbi.nlm.nih.gov/pubmed/32168769 http://dx.doi.org/10.3390/ijms21061907

Ejemplares similares

FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic
por: Sumida, Yoshio, et al.
Publicado: (2021)

Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods
por: Yoneda, Masato, et al.
Publicado: (2017)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020
por: Tokushige, Katsutoshi, et al.
Publicado: (2021)

Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease
por: Sumida, Yoshio, et al.
Publicado: (2020)

Eradication of hepatitis C virus with direct‐acting antivirals improves glycemic control in diabetes: A multicenter study
por: Takahashi, Hirokazu, et al.
Publicado: (2020)

A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD
por: Kawaguchi, Takumi, et al.
Publicado: (2018)

Infection phase is a predictor of pruritus in patients with hepatitis B virus infection
por: Oeda, Satoshi, et al.
Publicado: (2019)

Modification of a simple clinical scoring system as a diagnostic screening tool for non‐alcoholic steatohepatitis in Japanese patients with non‐alcoholic fatty liver disease
por: Nakamura, Akinobu, et al.
Publicado: (2013)

Soluble CD14 Levels Reflect Liver Inflammation in Patients with Nonalcoholic Steatohepatitis
por: Ogawa, Yuji, et al.
Publicado: (2013)

Association of Serum Albumin Levels and Long-Term Prognosis in Patients with Biopsy-Confirmed Nonalcoholic Fatty Liver Disease
por: Takahashi, Hirokazu, et al.
Publicado: (2023)

LDL-Migration Index (LDL-MI), an Indicator of Small Dense Low-Density Lipoprotein (sdLDL), Is Higher in Non-Alcoholic Steatohepatitis than in Non-Alcoholic Fatty Liver: A Multicenter Cross-Sectional Study
por: Imajo, Kento, et al.
Publicado: (2014)

Involvement of Periodontal Disease in the Pathogenesis and Exacerbation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis: A Review
por: Kobayashi, Takashi, et al.
Publicado: (2023)

Plasma Pentraxin3 is a Novel Marker for Nonalcoholic Steatohepatitis (NASH)
por: Yoneda, Masato, et al.
Publicado: (2008)

Association of Serum and Fecal Bile Acid Patterns With Liver Fibrosis in Biopsy-Proven Nonalcoholic Fatty Liver Disease: An Observational Study
por: Kasai, Yuki, et al.
Publicado: (2022)

Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin
por: Ogawa, Yuji, et al.
Publicado: (2018)

Questionnaire survey on lifestyle of patients with nonalcoholic steatohepatitis
por: Noto, Haruka, et al.
Publicado: (2014)

Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes
por: Ishiba, Hiroshi, et al.
Publicado: (2020)

Wilson's disease masquerading as nonalcoholic steatohepatitis
por: Mahmood, Sabina, et al.
Publicado: (2009)

Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis
por: Kessoku, Takaomi, et al.
Publicado: (2016)

The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
por: Honda, Yasushi, et al.
Publicado: (2016)

High Prevalence of Autoimmune Gastritis in Patients with Nonalcoholic Steatohepatitis
por: Kawanaka, Miwa, et al.
Publicado: (2019)

Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population
por: Sumida, Yoshio, et al.
Publicado: (2012)

Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis
por: Honda, Yasushi, et al.
Publicado: (2017)

Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model
por: Nozaki, Yuichi, et al.
Publicado: (2015)

Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers
por: Kawaguchi, Takahisa, et al.
Publicado: (2018)

Exercise changes the intrahepatic immune cell profile and inhibits the progression of nonalcoholic steatohepatitis in a mouse model
por: Tsutsui, Yuriko, et al.
Publicado: (2023)

A 3-step approach to predict advanced fibrosis in nonalcoholic fatty liver disease: impact on diagnosis, patient burden, and medical costs
por: Kobayashi, Takashi, et al.
Publicado: (2022)

Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Cirrhosis Confirmed by Liver Histology after 14 Years
por: Kawanaka, Miwa, et al.
Publicado: (2020)

Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD
por: Takahashi, Hirokazu, et al.
Publicado: (2021)

Treatment of nonalcoholic steatohepatitis with vitamins E and C: a pilot study
por: Kawanaka, Miwa, et al.
Publicado: (2013)

Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?
por: Kalogirou, Maria, et al.
Publicado: (2018)

The Clinical Difference in the Platelet Counts between Liver Cirrhosis with Nonalcoholic Fatty Liver Disease and Hepatitis C Virus
por: Ikarashi, Yuichi, et al.
Publicado: (2017)

Effect of miglitol on the suppression of nonalcoholic steatohepatitis development and improvement of the gut environment in a rodent model
por: Kishida, Yumi, et al.
Publicado: (2017)

Discordant pathological diagnosis of non‐alcoholic fatty liver disease: A prospective multicenter study
por: Kuwashiro, Takuya, et al.
Publicado: (2019)

Soluble CD163 is a predictor of fibrosis and hepatocellular carcinoma development in nonalcoholic steatohepatitis
por: Kawanaka, Miwa, et al.
Publicado: (2023)

Are Platelets Count Useful for Detecting the Grade of Steatosis?
por: Imajo, Kento, et al.
Publicado: (2015)

Use of Mac‐2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis
por: Kamada, Yoshihiro, et al.
Publicado: (2017)

SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum
por: Kamada, Yoshihiro, et al.
Publicado: (2022)

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
por: Seko, Yuya, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0us0pv6h7u7s2o0saciaumkj23